Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Calcitonin gene-related peptide Stories

2014-04-08 08:29:08

CARDIFF, Calif., April 8, 2014 /PRNewswire/ -- NI Research has released the April issue of NeuroPerspective, which reviews and assesses migraine therapeutics in development. Migraine is the most common of all neurological disorders. Based on epidemiological studies done in the US and Europe during the 1990s, approximately 12.6% of the population experiences migraine in a given year, with 18% suffering from migraine at some point in their lifetimes. It is estimated that there are 36...

2014-01-16 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 16, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Incyte Corporation (NASDAQ: INCY), and Varian Medical Systems Inc. (NYSE: VAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2014-01-13 08:26:30

Deal Represents Positive Milestone for Alternative R&D Funding Strategy INDIANAPOLIS, Jan. 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two...

2014-01-08 08:28:02

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects...

2013-10-15 21:04:49

Scientists at the University of Washington have used genetic engineering to identify a population of neurons that tell the brain to shut off appetite. Their study, "Genetic identification of a neural circuit that suppresses appetite," was published Oct. 13 in Nature. To identify these neurons, or cells that process and transmit information in the brain, researchers first considered what makes an animal lose its appetite. There are a number of natural reasons, including infection, nausea,...

2013-06-26 08:31:03

SAN MATEO, Calif., June 26, 2013 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for chronic migraine, today announced data from three late-breaking poster presentations demonstrating the pharmacokinetics and safety profile of LBR-101 (formerly RN-307) observed in multiple Phase 1 clinical studies. LBR-101 is a humanized monoclonal antibody that blocks the binding of CGRP to its receptor and is in development for the prevention of chronic migraine....

2013-06-24 12:26:11

DUBLIN, June 24, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kzmqb4/pain_management) has announced the addition of the "Pain Management Treatment Markets" [http://www.researchandmarkets.com/research/kzmqb4/pain_management ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Pain management drugs, or analgesics, can be categorized into three main modalities: acetaminophen, NSAIDs and...

2013-03-20 08:27:00

Company that Discovered and Developed Clazakizumab, Previously Known as ALD518, Advances New Program into Phase 2 Study BOTHELL, Wash., March 20, 2013 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody therapeutic candidate, ALD403, targeting calcitonin gene-related peptide (CGRP) for treatment of migraine. The double-blind, placebo-controlled, randomized study will evaluate the...

2013-03-18 08:29:07

SAN FRANCISCO, March 18, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced key executive appointments to lead the development of RN-307, a Phase 2 ready anti-CGRP monoclonal antibody for the treatment of chronic migraine. Marcelo Bigal, M.D., Ph.D., joins Labrys as chief medical officer, along with Michael Chang, Ph.D., as vice president of project management; Michele Bronson, Ph.D., vice president of regulatory and quality;...

2013-01-03 08:25:20

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P....